IL288743B2 - Compositions and methods relating to erythrocytes with adhesive particles - Google Patents

Compositions and methods relating to erythrocytes with adhesive particles

Info

Publication number
IL288743B2
IL288743B2 IL288743A IL28874321A IL288743B2 IL 288743 B2 IL288743 B2 IL 288743B2 IL 288743 A IL288743 A IL 288743A IL 28874321 A IL28874321 A IL 28874321A IL 288743 B2 IL288743 B2 IL 288743B2
Authority
IL
Israel
Prior art keywords
composition
ratio
subject
therapeutic agent
plga
Prior art date
Application number
IL288743A
Other languages
English (en)
Hebrew (he)
Other versions
IL288743B1 (en
IL288743A (en
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of IL288743A publication Critical patent/IL288743A/en
Publication of IL288743B1 publication Critical patent/IL288743B1/en
Publication of IL288743B2 publication Critical patent/IL288743B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL288743A 2019-06-07 2020-06-04 Compositions and methods relating to erythrocytes with adhesive particles IL288743B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962858478P 2019-06-07 2019-06-07
PCT/US2020/036040 WO2020247576A1 (en) 2019-06-07 2020-06-04 Compositions and methods relating to erythrocytes with adhered particles

Publications (3)

Publication Number Publication Date
IL288743A IL288743A (en) 2022-02-01
IL288743B1 IL288743B1 (en) 2024-10-01
IL288743B2 true IL288743B2 (en) 2025-02-01

Family

ID=73652929

Family Applications (1)

Application Number Title Priority Date Filing Date
IL288743A IL288743B2 (en) 2019-06-07 2020-06-04 Compositions and methods relating to erythrocytes with adhesive particles

Country Status (8)

Country Link
US (1) US20220323603A1 (https=)
EP (1) EP3979994A4 (https=)
JP (1) JP7561146B2 (https=)
CN (1) CN114222564A (https=)
AU (1) AU2020287620B2 (https=)
CA (1) CA3140681A1 (https=)
IL (1) IL288743B2 (https=)
WO (1) WO2020247576A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3180060A1 (en) * 2020-05-29 2021-12-02 Zongmin ZHAO Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
WO2023288046A1 (en) 2021-07-15 2023-01-19 President And Fellows Of Harvard College Compositions and methods relating to cells with adhered particles
CN118871571A (zh) * 2022-03-11 2024-10-29 西湖生物医药科技(上海)有限公司 一种靶向pd-1的工程化红细胞
WO2026046110A1 (zh) * 2024-08-26 2026-03-05 西湖生物医药科技(杭州)有限公司 一种基于工程化红细胞的新型药物递送系统

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004032970A2 (en) * 2002-10-10 2004-04-22 Samir Mitragotri Carriers attached to blood cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6998393B2 (en) * 2000-06-23 2006-02-14 Biopharm Solutions, Inc. Aquespheres, their preparation and uses thereof
WO2007084460A2 (en) * 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
EP2714017B1 (en) 2011-06-02 2018-08-01 The Regents of The University of California Membrane encapsulated nanoparticles and method of use
US11400114B2 (en) * 2016-03-15 2022-08-02 Massachusetts Institute Of Technology Synthetically functionalized living cells for targeted drug delivery
JP6888239B2 (ja) 2017-06-28 2021-06-16 株式会社 ＳＥＮＴＡＮ Ｐｈａｒｍａ 腫瘍治療用腫瘍免疫活性促進剤及び腫瘍治療用医薬組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004032970A2 (en) * 2002-10-10 2004-04-22 Samir Mitragotri Carriers attached to blood cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRENNER JACOB S. ET AL,, RED BLOOD CELL-HITCHHIKING BOOSTS DELIVERY OF NANOCARRIERS TO CHOSEN ORGANS BY ORDERS OF MAGNITUDE, 11 July 2018 (2018-07-11) *
ZELEPUKIN I. V. ET AL,, NANOPARTICLE-BASED DRUG DELIVERY VIA RBC-HITCHHIKING FOR THE INHIBITION OF LUNG METASTASES GROWTH, 23 January 2019 (2019-01-23) *

Also Published As

Publication number Publication date
JP7561146B2 (ja) 2024-10-03
EP3979994A1 (en) 2022-04-13
IL288743B1 (en) 2024-10-01
IL288743A (en) 2022-02-01
EP3979994A4 (en) 2023-08-09
US20220323603A1 (en) 2022-10-13
AU2020287620A1 (en) 2022-01-06
AU2020287620B2 (en) 2025-12-18
CN114222564A (zh) 2022-03-22
CA3140681A1 (en) 2020-12-10
WO2020247576A1 (en) 2020-12-10
JP2022534796A (ja) 2022-08-03

Similar Documents

Publication Publication Date Title
Basak et al. Tumor-associated macrophages: an effective player of the tumor microenvironment
Bourquin et al. Harnessing the immune system to fight cancer with Toll-like receptor and RIG-I-like receptor agonists
IL288743B2 (en) Compositions and methods relating to erythrocytes with adhesive particles
Shen et al. Intravesical treatments of bladder cancer
JP5704788B2 (ja) 癌の治療および過剰増殖性疾患の治療のための、免疫遺伝子療法と化学療法の組み合わせ
JP6731405B2 (ja) ウイルス粒子を用いた癌免疫療法
DE69928093T2 (de) Kombinationspräparat enthaltend monozyten-abgeleitete zellen zur behandlung von neoplastischen oder infektiösen erkrankungen
JP2022534796A5 (https=)
KR20100123674A (ko) 나노치료제 콜로이드성 금속 조성물 및 방법
Wang et al. Targeting macrophage anti-tumor activity to suppress melanoma progression
US20230287075A1 (en) Dual cytokine fusion proteins comprising multi-subunit cytokines
CN102149391A (zh) 用于治疗肿瘤疾病的组合物和方法
KR960008009B1 (ko) 인터류킨 및 이중-가닥 rna를 포함하는 상승작용화 조성물
Li et al. A novel C type CpG oligodeoxynucleotide exhibits immunostimulatory activity in vitro and enhances antitumor effect in vivo
JPH06501017A (ja) 充実性腫瘍の処置のためのｉｌ−４の使用
TWI910445B (zh) 作為治療疫苗之奈米顆粒
CN118542841A (zh) 用于治疗癌症的免疫修饰粒子
Thotathil et al. Early experience with novel immunomodulators for cancer treatment
US20230106313A1 (en) A bacterial composition for the treatment of cancer
Hołowiecki et al. G-CSF administered in time-sequenced setting during remission induction and consolidation therapy of adult acute lymphoblastic leukemia has beneficial influence on early recovery and possibly improves long-term outcome: a randomized multicenter study
US10760054B2 (en) Natural killer cells and methods for enhancing viability, proliferation and cytotoxicity of same following cryopreservation
CN116271090B (zh) 一种具有tlr9激动剂活性的dna纳米笼及其在制备抗肿瘤药物中的应用
CN119185520A (zh) 一种仿生自噬小体的肿瘤纳米疫苗及其制备方法与应用
Hasibuzzaman et al. Characterization of CPH: SA microparticle‐based delivery of interleukin‐1 alpha for cancer immunotherapy
CN118715239A (zh) 包含多亚基细胞因子的双细胞因子融合蛋白